Definition and epidemiology
Coronaviruses are enveloped, single-stranded positive-sense RNA viruses that infect respiratory and gastrointestinal epithelium in humans and animals. Human-pathogenic strains include seasonal coronaviruses (229E, OC43, NL63, HKU1) causing the common cold, and three strains causing severe outbreaks: SARS-CoV (2002-2003), MERS-CoV (2012-present, Middle East), and SARS-CoV-2, the cause of the COVID-19 pandemic beginning in late 2019.
- SARS-CoV-2 spread globally, with hundreds of millions of confirmed cases and millions of deaths reported worldwide since 2020
- Case fatality rate varies widely by age, comorbidity, and viral variant, and has declined substantially with vaccination and population immunity
- Seasonal coronaviruses are a common cause of mild upper respiratory infections, especially in winter months
- MERS-CoV has a much higher case fatality rate (around 35%) but limited human-to-human transmission, with cases concentrated in the Arabian Peninsula
- SARS-CoV-2 enters cells via ACE2 receptor, primed by TMPRSS2
- Anosmia/dysgeusia is a relatively specific early symptom for COVID-19
- MERS-CoV uses DPP4 as its receptor, not ACE2
- Bilateral peripheral ground-glass opacities are the classic CT finding
- Dexamethasone reduces mortality only in patients needing supplemental oxygen
- Elevated D-dimer and lymphopenia correlate with disease severity
- RT-PCR is the diagnostic gold standard; antigen tests are faster but less sensitive
- Silent hypoxemia can mask severe disease on initial presentation
Etiology and risk factors
Infection follows exposure to respiratory droplets, aerosols, or contaminated surfaces (fomites), with aerosol transmission considered the dominant route for SARS-CoV-2 in enclosed, poorly ventilated spaces.
Risk factors for severe disease
- Older age (especially over 65 years)
- Obesity, diabetes mellitus, cardiovascular disease
- Chronic lung disease (COPD, asthma)
- Immunosuppression (transplant, chemotherapy, uncontrolled HIV)
- Chronic kidney disease
- Pregnancy
- Unvaccinated status
Animal reservoirs are implicated in zoonotic spillover for SARS-CoV, MERS-CoV (dromedary camels), and SARS-CoV-2 (proposed bat/intermediate host origin, though the precise origin remains debated).
Pathophysiology
SARS-CoV-2 spike protein binds angiotensin-converting enzyme 2 (ACE2) receptors, which are abundant on type II pneumocytes, nasal and bronchial epithelium, and vascular endothelium. Cellular entry also requires priming by the host protease TMPRSS2.
- Initial viral replication occurs in the upper respiratory tract, producing mild symptoms in most patients
- Progression to lower respiratory tract involvement can trigger diffuse alveolar damage and an exaggerated host inflammatory response ("cytokine release"), driving ARDS in severe cases
- Endothelial injury and a hypercoagulable state increase risk of venous thromboembolism and microvascular thrombosis
- Multisystem effects can involve the heart (myocarditis), kidney (acute kidney injury), and nervous system (anosmia, encephalopathy)
- MERS-CoV instead uses dipeptidyl peptidase-4 (DPP4) as its receptor
Clinical features
Presentation ranges from asymptomatic infection to critical illness.
Common symptoms
- Fever, cough (usually dry), sore throat, myalgia, fatigue
- Anosmia or dysgeusia (loss of smell/taste) — more specific for COVID-19 than other respiratory viruses
- Dyspnea, which may develop in the second week of illness
- Gastrointestinal symptoms (nausea, diarrhea) in a subset of patients
Severe disease
- Hypoxemia, tachypnea, and signs of respiratory distress
- Progression to ARDS, septic shock, or multiorgan failure
- Silent hypoxemia (low oxygen saturation without obvious dyspnea) is a notable pitfall
Post-acute sequelae
A subset of patients develop persistent symptoms ("long COVID"), including fatigue, dyspnea, brain fog, and exercise intolerance lasting weeks to months.
Diagnosis
Diagnosis combines clinical suspicion with laboratory and, when indicated, imaging confirmation.
Testing
- Reverse transcription PCR (RT-PCR) on nasopharyngeal or oropharyngeal swab is the diagnostic gold standard
- Rapid antigen tests are faster but less sensitive, especially early or late in infection
- Serology (antibody testing) indicates past infection or vaccination, not useful for acute diagnosis
Imaging and labs
- Chest CT in moderate-severe disease classically shows bilateral peripheral ground-glass opacities
- Chest X-ray may be normal early in mild disease
- Lymphopenia, elevated D-dimer, ferritin, CRP, and LDH correlate with severity
| Test | Role |
|---|---|
| RT-PCR | Confirms active infection, gold standard |
| Antigen test | Rapid screening, lower sensitivity |
| Chest CT | Assesses extent of pneumonia in symptomatic hospitalized patients |
| D-dimer, ferritin, CRP | Risk-stratify severity, not diagnostic alone |
Differential diagnosis
- Influenza (clinically similar; co-testing often performed during overlapping seasons)
- Other respiratory viral infections (RSV, rhinovirus, parainfluenza)
- Community-acquired bacterial pneumonia
- Pulmonary embolism (can mimic or complicate COVID-19, both cause dyspnea and hypoxemia)
- Acute bronchitis
- Allergic rhinitis (for isolated upper respiratory symptoms without fever)
Management
Management is stratified by disease severity and risk for progression; recommendations continue to evolve and differ somewhat between WHO, US (NIH/CDC/IDSA), and European (ECDC) guidance.
Mild/outpatient disease
- Supportive care: rest, hydration, antipyretics/analgesics (e.g., acetaminophen)
- Antiviral therapy (e.g., nirmatrelvir-ritonavir, or remdesivir where appropriate) considered for patients at high risk of progression, ideally started early in the illness course
- Isolation per local public health guidance to limit transmission
Moderate-severe/hospitalized disease
- Supplemental oxygen as needed; high-flow oxygen or noninvasive/invasive ventilation for respiratory failure
- Corticosteroids (dexamethasone) for patients requiring supplemental oxygen, reducing mortality in this group
- Remdesivir considered in selected hospitalized patients, particularly those requiring oxygen but not yet on mechanical ventilation
- Immunomodulators (e.g., tocilizumab, baricitinib) considered in rapidly deteriorating patients with significant inflammation, per specialist guidance
- Anticoagulation (prophylactic dose typically) given elevated thrombosis risk
- Avoid routine antibiotic use unless bacterial superinfection is suspected
Prevention
- Vaccination remains the cornerstone of prevention and reduces severe disease and death
- Infection control measures: masking, ventilation, hand hygiene, isolation of cases
- Monoclonal antibodies have had variable efficacy depending on circulating variants and are not consistently recommended currently
Complications and prognosis
Most infections, especially in vaccinated and younger populations, are mild and self-limited.
Complications
- ARDS and respiratory failure
- Venous thromboembolism (DVT, pulmonary embolism) and arterial thrombosis
- Myocarditis, arrhythmias
- Acute kidney injury
- Secondary bacterial pneumonia
- Multisystem inflammatory syndrome (rare, more recognized in children, MIS-C)
- Post-acute sequelae ("long COVID")
Prognosis
Prognosis correlates strongly with age, comorbidity burden, vaccination status, and timeliness of care. Mortality is highest in elderly and immunocompromised patients, while most healthy individuals recover fully within 1-2 weeks.
"CROWN" for coronavirus features: Cough, Respiratory distress (severe), Overactive immune response (cytokine storm), Weakened smell/taste (anosmia), Need for oxygen (hypoxemia)
Practice questions
1. A 68-year-old man with type 2 diabetes presents with 6 days of fever, dry cough, and new dyspnea. Oxygen saturation is 89% on room air. Chest CT shows bilateral peripheral ground-glass opacities. He is started on supplemental oxygen. Which additional therapy is most appropriate at this time?
2. A 34-year-old nurse develops fever, cough, and sudden loss of smell three days after caring for a COVID-19 positive patient. She is otherwise healthy and has mild symptoms. What is the most appropriate next step?
3. A 45-year-old camel herder in Saudi Arabia presents with fever, cough, and respiratory failure. PCR confirms a coronavirus distinct from SARS-CoV-2. Which receptor does this virus most likely use for cell entry?
Frequently asked questions
What causes coronavirus infection?
Coronavirus infections are caused by RNA viruses of the Coronaviridae family, including SARS-CoV-2 (COVID-19), MERS-CoV, SARS-CoV, and several seasonal strains that cause common colds. Transmission occurs mainly through respiratory droplets and aerosols, and less commonly through contaminated surfaces. SARS-CoV-2 spreads efficiently between humans, especially in crowded or poorly ventilated indoor spaces.
What are the first symptoms of coronavirus infection?
The earliest symptoms are typically fever, dry cough, sore throat, fatigue, and muscle aches, similar to other respiratory viruses. Loss of smell or taste is a more distinctive early feature. Symptoms usually appear 2-14 days after exposure, with most people developing symptoms around day 5.
How is coronavirus infection diagnosed?
Diagnosis is confirmed with RT-PCR testing on a nasal or throat swab, which is the most accurate test available. Rapid antigen tests provide quicker results but are less sensitive, particularly early in infection. Chest CT and inflammatory markers help assess severity in patients with more significant respiratory symptoms.
Is coronavirus infection curable?
Most coronavirus infections resolve on their own with supportive care within one to two weeks. There is no single "cure," but antiviral medications can shorten illness and reduce progression to severe disease in high-risk patients when started early. Severe cases require hospital-level supportive care, and vaccination substantially reduces the risk of severe outcomes.
COVID-19 vs influenza — what is the difference?
Both cause fever, cough, and fatigue, but COVID-19 more often causes anosmia or dysgeusia, which is less common in influenza. Influenza tends to have a shorter incubation period and faster symptom onset, while COVID-19 can have a more variable course with later deterioration in the second week. Specific testing (PCR panels) is needed to distinguish them reliably since clinical overlap is substantial.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: B97.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.